Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Life sciences companies have decided to chop hundreds of Bay Area jobs in a fresh wave of layoffs that hint at ongoing ...

Gilead Sciences, Inc., a biopharmaceutical company ... The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights ...

Gilead is laying off 149 workers in Foster City and Roche is laying off 108 workers in Santa Clara, adding to the mounting ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from $120.00 to $130.00 in a research note issued to investors on Thursday ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...